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Abstract
Introduction—This study assessed the period prevalence (2000-2008) and mortality rates of 
melanoma, in Oklahoma, among different racial/ethnic strata.
Methods—We analyzed incident cases of melanoma from 2000-2008 from the Oklahoma 
Central Cancer Registry and determined disease duration using Kaplan-Meier survival analysis to 
calculate period prevalence of melanoma in Oklahoma. Using a series of Chi-Square tests, we 
compared period prevalence and mortality rates among the racial groups and compared mortality 
between Oklahoma and the US.
Results—White non-Hispanics in Oklahoma have the highest period prevalence (p<0.0001) 
among the racial strata. American Indian or Alaska Native (AI/AN) individuals have the second 
highest period prevalence in Oklahoma (p<0.0001). Furthermore, white non-Hispanics (p<0.0001) 
and AI/AN individuals (p=0.0003) in Oklahoma had higher mortality rates compared to the US.
Conclusions—There are disparities in the prevalence and mortality of melanoma among the 
AI/AN population in Oklahoma, and prevention and education programs should focus on this 
population.
INTRODUCTION
Melanoma is a malignancy of the melanocytes, the cells responsible for pigmentation of the 
skin, visceral organs, eyes and ears.1 The incidence of melanoma in the United States has 
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risen over the last few decades.2-6 Melanoma incidence has been increasing on average 
2.6-2.9% per year since 1981.7,8 This rise in incidence is concerning since melanoma is 
considered preventable through proper precautions.9 Melanoma is a serious condition, with 
9,940 individuals in the US estimated to die from melanoma in 2015.10 Disparities in 
melanoma incidence, stage, and mortality are evident in the literature among racial groups in 
the US.9,11-20 Most of these studies are based on national or regional data. Few studies have 
focused on the disparities in the prevalence and mortality of melanoma among racial groups 
in a single state, especially in a state with large numbers of American Indian and Alaska 
Native (AI/AN) individuals like Oklahoma. Oklahoma is unique in that there is a large 
proportion of AI/AN individuals alone (9% as compared 1.2% nationally).21 In fact, 
Oklahoma has the second largest population of AI/AN in the US, after California.21 A single 
study has investigated the disparities between the white and AI/AN populations in 
Oklahoma.22 That study observed that AI/AN individuals in Oklahoma had significantly 
higher overall cancer incidence than whites (629.8/100,000 vs. 503.3/100,000), and their 
disease was diagnosed at a later stage than the white population (14.0% in white vs. 20.0% 
in AI/AN).22 It focused on incident data between the white and AI/AN populations, and 
clearly quantified the disparities between the two racial groups. Although limited to 
Oklahoma, that study focused on all cancers combined and was not specific to addressing 
melanoma alone.
Disparities in melanoma mortality among racial groups is also evident, another study 
reported the mortality from melanoma was significantly higher in white individuals in the 
South, including Oklahoma.23 This study focused on mortality in a region with no specific 
information about individuals in Oklahoma. Due to a different population distribution in 
Oklahoma, specifically among AI/AN individuals, mortality rates may differ from that study 
population. Also, a later stage melanoma at diagnosis is linked to higher mortality.3,6,8 
Because of this, melanoma stage at diagnosis for the different racial groups is examined 
along with mortality.
The purpose of this study was to describe the burden of melanoma by estimating the stage at 
diagnosis, period prevalence, and mortality from 2000-2008 by race in Oklahoma. This is 
the first study that has estimated race-specific prevalence proportions in Oklahoma. 
Additionally, we investigated racial disparities in melanoma mortality rates in Oklahoma and 
compared those rates to national mortality rates.
METHODS
This study used data from the Oklahoma Central Cancer Registry (OCCR), which is coded 
according to the North American Association of Central Cancer Registries (NAACCR) 
standards. All statistical testing and calculations were performed with SAS 9.3 statistical 
software. The registry data were limited to incident cases of melanoma diagnosed between 
the years 2000 and 2008 among Oklahoma residents. We included those with SEER ICD-
O-3 histology codes between 8720 to 8790 and site codes of skin of the lip, eyelid, ear, head, 
neck, trunk, and extremities (C44.0-C44.9); labia and clitoris (C51.0-C51.2); vulva (C51.8-
C51.9); penis (C60.0-C60.2, C60.8-C60.9); and scrotum (C63.2) according to SEER site 
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codes.24 Individuals with unknown ICD-O-3 codes were excluded from the analysis. Cases 
diagnosed upon autopsy or from a death certificate only were also excluded.
The registry data were recoded for race and ethnicity, using the following race and ethnic 
groups: White non-Hispanic, White Hispanic, African American, AI/AN, and Asian and 
Pacific Islander. To ensure correct classification of AI/AN individuals, each incident case in 
the OCCR data was cross referenced with the Indian Health Service (IHS) registration 
database and those that matched were reported as AI/AN. Individuals whose racial 
classification was unknown or missing were excluded from the analysis.
We determined the percent of OCCR incident cases diagnosed at each SEER stage, and the 
percentage of individuals among the racial strata diagnosed with a late stage of melanoma. 
Late stage melanoma was defined as anyone that had regional or distant stage according to 
SEER staging guidelines.25 The proportions of each racial strata diagnosed at late stage were 
compared using a series of Chi-Square tests.
To estimate prevalence from the OCCR incidence data, the mean duration of melanoma was 
determined for individuals within each race/ethnicity. We estimated duration for individuals 
by determining the number of days between last follow-up date obtained by the OCCR and 
date of diagnosis. Individuals who lived through the entirety of the OCCR study period were 
assumed to be alive as of November 1, 2014. We used the Kaplan-Meier estimates of mean 
survival time to estimate the duration of melanoma for each racial/ethnic stratum. To 
determine whether the mean survival time differed by race/ethnicity, we used the log-rank 
test for Kaplan-Meier analysis. We found mean survival did differ by race, so the mean 
survival time was determined by racial strata, and used as an estimation of the duration of 
melanoma. Since we used the mean survival to calculate prevalent cases, all-cause mortality 
was included in the individuals who died during the period.
The number of prevalent cases for each race/ethnic group during the period from 2000 to 
2008 was estimated using the relationship between incidence and duration in a steady state 
population: Prevalence ≈ Incidence × Duration.26 The number of prevalent cases of 
melanoma in Oklahoma was estimated using the OCCR incident cases from 2000 to 2008, 
and the estimated duration from the mean survival in the Kaplan-Meier analysis. Similarly, 
the product of the estimated duration and the total incident cases rendered estimates of the 
prevalent cases in each race/ethnic group over the period. To arrive at an estimated period 
prevalence per 100,000 persons, the estimated number of prevalent cases was divided by the 
population in each racial category over the 9-year period. Denominators for period 
prevalence came from SEER’s annual estimates of Oklahoma’s population from 2000 to 
2008.27 The annual population in each racial category was totaled over the 9-year period. 
Period prevalence for each racial category was calculated by dividing the group’s prevalent 
cases by the group’s total period population. Finally, we calculated 95% confidence intervals 
on each estimated population proportion.28 Period prevalence for each of the racial 
categories were compared using Chi-Square tests.
The crude and age-adjusted melanoma mortality rates by race in Oklahoma, over the same 
period, were determined using the final cancer mortality statistics from the Oklahoma State 
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Department of Health website, OK2Share.29 Crude and age-adjusted mortality rates were 
reported in the same race/ethnicity categories used in the prevalence calculations, and all 
individuals were IHS-linked to ensure more accurate classification of individuals who were 
AI/AN by adjusting for racial misclassification. The national crude and age-adjusted 
mortality rates were obtained from the CDC’s WONDER cancer statistics, from 
2000-2008.30 The Oklahoma mortality rates were then compared to national mortality rates 
using a series of Chi-Square tests in the same racial categories. Asian or Pacific Islander 
mortality rates in Oklahoma could not be compared due to the suppressed Oklahoma state 
data (n<5).
RESULTS
From the OCCR, we identified 6,962 incident cases of melanoma in Oklahoma from 
2000-2008. Of those cases, 88 had missing or unknown racial status and were eliminated, 
leaving 6,874 for the prevalence analysis. The data included 6,418 white individuals 
(93.4%), 341 AI/AN individuals (5.0%), 62 white Hispanic individuals (1.0%), 36 African 
American individuals (0.5%), and 17 Asian/Pacific Islanders (0.3%). The population of 
incident cases over the period consisted of 59% male and 41% female individuals (Table 1).
Among the incident cases of melanoma over the period, 1,676 (28.8%) were staged as in 
situ, 3,246 (55.8%) as localized, 469 (8.1%) as regional, and 426 (7.3%) as distant. A series 
of Chi-Square tests indicated that white Hispanics (21.2%, p=0.22), African Americans 
(17.2%, p=0.74), and Asian/Pacific Islanders (14.3%, p=0.93) did not differ from white non-
Hispanics (15.1%) in the proportion diagnosed at late stage melanoma. However, AI/AN 
individuals (20.1%, p=0.02) had a higher proportion of individuals diagnosed at late-stage of 
melanoma compared to white non-Hispanics. We were unable to analyze 1,057 individuals 
for stage at diagnosis because of missing staging information, although these individuals 
were included in the prevalence estimates.
Prevalence Estimates
Of the 6,874 incident cases, 6,846 cases were included in the Kaplan-Meier analysis, 2,381 
(34.8%) died from all causes over the period from 2000-2008. We excluded 26 individuals 
from the survival analysis with unknown or missing follow up information. Overall survival 
did differ among racial groups (p from log rank test=0.03) (Figure 1). Estimated period 
prevalence for each racial stratum along with confidence interval are reported in Table 2.
White non-Hispanic individuals had a significantly higher period prevalence (233.0 per 
100,000; 95% CI: 231.3, 235.0) than any other racial strata (p<0.0001). African Americans 
had the lowest period prevalence (8.0 per 100,000; 95%CI: 7.2, 9.2) when compared to the 
other racial categories (p<0.0001). We observed a period prevalence of 88.0 (95% CI: 85.1, 
91.4) per 100,000 among AI/ANs, which was significantly higher than white Hispanics, 
African Americans, and Asian/Pacific islanders (p<0.0001).
Mortality
Regarding mortality, there were 1,141 melanoma deaths over the period 2000-2008.29 Of the 
total deaths in the period, 1,091 (95.6%) where in white non-Hispanic individuals, 8 (0.7%) 
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in white Hispanic individuals, 7 (0.6%) in African American individuals, and 35 (3.1%) 
were in AI/AN individuals. Both crude and age adjusted melanoma mortality rates among 
racial categories in Oklahoma and the United States are presented in Table 3. The crude 
melanoma mortality rate for Oklahoma white non-Hispanics was 4.6 deaths per 100,000, 
which was higher than the national white non-Hispanic crude mortality rate of 3.9 deaths per 
100,000 (p<0.0001). The age adjusted mortality rate in Oklahoma was also higher than age 
adjusted national rate. The crude melanoma mortality rates for white Hispanics (p=0.99) and 
African Americans (p=0.66) in Oklahoma did not differ from the national crude mortality 
rates. The crude melanoma mortality rate for AI/AN individuals in Oklahoma was higher 
than the national crude melanoma mortality rate (p=0.0003). The age adjusted mortality rate 
was also higher among AI/AN individuals in Oklahoma compared to the national age 
adjusted rate. Also, AI/AN individuals in Oklahoma had a higher crude melanoma mortality 
rate than white Hispanics (p=0.0053) and African Americans (p<0.0001) in Oklahoma.
DISCUSSION
The majority of cases of melanoma were in the white non-Hispanic population, with 
approximately 6% of the incident cases over the nine years occurring in other racial groups. 
This distribution of melanoma in the population of Oklahoma was similar to data from other 
studies on melanoma, indicating that fairer skin is a risk factor in the development of 
melanoma.2-4,9,13,15,19 More cases were seen among men than among women, which also 
followed the distribution of melanoma studied in previous studies.2-3,9,13 We found that 
AI/AN individuals demonstrated the second highest prevalence of melanoma, after whites 
non-Hispanics.
Members of non-white populations are typically diagnosed with melanoma at later stages 
than white individuals. 2,4,11-15,18,31 Similar to previous results of we observed that AI/AN 
individuals in Oklahoma are diagnosed at a significantly higher stage of melanoma than 
white non-Hispanics. These studies reinforce the need for enhanced melanoma education at 
the individual and primary care physician level for AI/AN individuals. Korta and his 
colleagues stated that whites differ from other racial groups in their ability to identify 
melanoma visual characteristics on a self-exam.14 Continued research among the AI/AN 
population in effective educational programs for skin lesion identification, and melanoma 
prevention strategies could prove beneficial. These results may help stimulate more intense 
prevention strategies or educational programs through the extensive Indian Health Service, 
Tribal health programs, and urban clinics throughout Oklahoma.
In our analysis, we observed the crude mortality rate of white non-Hispanics in Oklahoma 
was significantly higher than the crude mortality rate for white non-Hispanics in the United 
States. Also, we observed the white non-Hispanic age-adjusted mortality rates were higher 
in Oklahoma compared to the U.S. This could indicate that Oklahoman white non-Hispanics 
were diagnosed at a later stage than white non-Hispanics in other parts of the United States. 
In addition, these cases may reflect the high proportion of rural residents of Oklahoma and 
may indicate problems with access to medical care. Further studies should be conducted to 
determine the stage of melanoma at diagnosis in Oklahoman white non-Hispanics and the 
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rest of the country. If the disparity in stage exists, it may also be evidence of lack of 
education and prevention knowledge, or failure to comply with personal safety practices.
Furthermore, we observed that AI/AN individuals of Oklahoma have a significant difference 
in crude melanoma mortality when compared to the U.S., and the age-adjusted rate is higher 
as well. Much like the prevalence data reported, melanoma mortality is approximately 2-3 
times higher in AI/AN individuals in Oklahoma than other non-white racial groups, which is 
also evident in the national data. This could indicate a disparity in melanoma early detection 
in the AI/AN population, not just in Oklahoma but nationally as well. We observed that 
melanoma was diagnosed at a later stage in AI/AN individuals in Oklahoma compared to 
non-Hispanic whites.22
Due to the higher prevalence and mortality rates of melanoma in Oklahoma, research into 
melanoma educational and prevention tactics in Oklahoma is important to determine 
whether Oklahomans are being undereducated compared to individuals in other states. 
Development of educational opportunities and programs to increase awareness of melanoma 
could positively impact the mortality among all racial groups in Oklahoma. Increased 
research into educational programs or even screening/prevention programs in the white non-
Hispanic and AI/AN population is recommended to determine if different programs could 
decrease the prevalence and mortality of melanoma in these Oklahomans.
There are multiple limitations to this study. The mean duration used in the calculation of 
estimated prevalence was a limiting factor. First of all, if the mean survival is not a good 
indicator of duration then this would affect the prevalence results either positively or 
negatively. Also, there were many individuals categorized as alive by the survival analysis 
that had a last follow up in excess of a year prior to the end of the follow-up period. The 
OCCR does passive linkage with state and national death data, and use of a passive system 
has been shown to over- estimate survival data for some groups, but generally estimates 
survival with similar quality as SEER methodology.32,33 Treating censored observations in 
this manner may have overestimated survival times, which would consequently overestimate 
prevalence. Of concern is that NDI linkage is not completed each year at OCCR. The large 
majority of cases will be updated with Oklahoma Mortality Data and the Social Security 
Death Index to identify those who are deceased. It is possible that this resulted in an 
artificial inflation of the rates for recent years. Another limitation to between-group 
comparisons of the mean duration was the small sample sizes for African Americans, Asian 
and Pacific Islanders, and Hispanics. The Kaplan Meier log rank test did indicate a 
difference in the mean survival between races. Much of the literature focused on melanoma 
does indicate that minorities are usually diagnosed at a later stage of melanoma when 
compared to whites.2,4,11-15,18,31 Later stage at diagnosis would affect survival, and that 
duration would follow and be different among racial strata. However, due to small sample 
sizes in the African American, White Hispanic, and Asian and Pacific Islander populations 
these mean survival times may be skewed toward longer survival. If this is the case, we may 
have assumed falsely longer durations for these racial stratum. One possible remedy for this 
is to conduct a regional study including states surrounding Oklahoma, which would increase 
the sample size overall and enhance the precision. Including a larger sample size could 
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possibly allow us to detect a more accurate difference in survival in each race/ethnicity, thus 
making the prevalence estimates more accurate.
This study approximated prevalence by combining incidence and the duration of melanoma. 
This calculation is based off the relationship between incidence, duration, and prevalence in 
a steady state population, which is when the rate of immigration equals the rate of 
emigration.26 Oklahoma was assumed to be under this steady state for the time period 
2000-2008. From 2000-2008, Oklahoma’s population grew at a rate of 5.6%, indicating that 
the population was not in steady state.21,34 Violation of this assumption would skew period 
prevalence estimated by the steady state population relationship.
Racial misclassification is also a limitation to this study. Steps were taken to adjust for 
AI/AN racial misclassification through linkage with IHS records. If the individual was 
unaware of family history, or have never been registered at an IHS, tribal facility, or urban 
AI/AN facility, then these individuals may continue to be misclassified.
Furthermore, socioeconomic status or access to health care was not taken into consideration 
for the mortality data. Many Oklahomans (n=1,266,322; 33.8%) live in small rural 
communities with limited access to health care.35 Also, these individuals may be required to 
travel to one of the major metropolitan areas to have access to specialized health care 
services. Future studies focusing on the prevalence, incidence, and mortality from melanoma 
in Oklahoma or the United States that address these confounders could prove advantageous.
This study was the first study to estimate the prevalence of melanoma in the population of a 
state with a high proportion of AI/AN. Furthermore, this study was the only study that 
focuses on racial differences in the prevalence and mortality of melanoma in Oklahoma, 
while attempting to reduce misclassification of AI/AN individuals through the IHS linkage. 
In conclusion, we observed a higher prevalence of melanoma among AI/AN individuals in 
Oklahoma than among other non-white racial groups. Oklahoma and national melanoma 
mortality rates were significantly different in the AI/AN population, also we found 
differences in mortality among the white non-Hispanic individuals in Oklahoma and the 
U.S. With the growing incidence of melanoma,2-8 research should be intensified to 
determine more effective methods to use in educational programs for both the public and 
health care providers. In addition, continued research into the burden of all cancers should 
be conducted in populations with high proportions of AI/AN individuals, with the goal of 
describing disparities between detection and care among AI/AN individuals.
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Figure 1. 
Overall survival among those with incidence cases of melanoma (n=6,846) by race/ethnicity 
in Oklahoma, 2000-2008.
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Table 1
Number of Incident Cases of Melanoma, by Sex and Race/Ethnic group, in Oklahoma, 2000-2008
Race/Ethnicity Male
N (%)
Female
N (%)
Total
White Non-Hispanic 3831 (94.7) 2587 (91.5) 6418
White Hispanic 16 (0.4) 46 (1.6) 62
African American 23 (0.6) 13 (0.5) 36
American Indian or
Alaska Nativea
170 (4.2) 170 (6.0) 340
Asian or
Pacifc Islander
6 (0.2) 11 (0.4) 17
Total 4046 (58.9) 2827 (41.1) 6873
a1 individual missing gender information
J Okla State Med Assoc. Author manuscript; available in PMC 2016 November 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Baldwin et al. Page 12
Table 2
Incident cases, Estimated Duration, Prevalent Cases, and Period Prevalence (2000-2008) of Melanoma by 
Race in Oklahoma
Race Incident
Cases
Median Duration,
Years (95%CI)a
Prevalent
Cases
Total
Population
(2000-
2010)
Period Prevalence
per 100,000 (95%CI)
White Non-Hispanic 6,418 9.6 (9.5, 9.7) 61,613 26,424,019 233 (231.3, 235.0)
White Hispanic 62 7.9 (7.2, 8.6) 490 2,144,709 23 (20.8, 24.7)
African American 36 6.7 (5.5, 7.9) 241 2,944,772 8 (7.2, 9.2)
American Indian or Alaska Native 341 8.9 (8.4, 9.5) 3,035 3,437,654 88 (85.1, 91.4)
Asian or Pacifc Islander 17 7.4 (6.4, 8.4) 126 653,100 19 (15.9, 22.7)
a
Estimated mean survival from Kaplan-Meier analysis.
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Table 3
Crude and Age-Adjusted Melanoma Mortality Rates in Oklahoma and the United States, 2000-2008 (per 
100,000).
Race/Ethnicity Crude Mortality
Rate Oklahomaa
Age-Adjusted
Mortality Rate
Oklahomaa
Crude Mortality
Rates United
Statesb
Age-Adjusted
Mortality Rates
United Statesb
White Non-Hispanic 4.6 (4.3, 4.9) 3.9 3.9 (3.8, 3.9) 3.3
White Hispanic 0.4 (0.1, 0.7) 0.8 0.4 (0.4, 0.5) 0.8
African American 0.3 (0.1, 0.5) 0.4 0.3 (0.3, 0.3) 0.5
American Indian or Alaska Native 1.2 (0.8, 1.6) 1.7 0.7 (0.5, 0.7) 1.0
Asian or Pacifc Islanderc NA NA 0.3 (0.2, 0.3) 0.4
aAge-Adjusted Mortality Rate data from OK2Share29
b
Data from CDC WONDER30
cAsian or Pacific Islander deaths suppressed by OK2Share due to low numbers (n<5)
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